Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for fabry disease

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Nguyen Dinh Cat, Aurelie ^a,b   Escoubet, Brigitte ^a,c,d   Agrapart, Vincent ^a,b   Griol Charhbili, Violaine ^a,b   Schoeb, Trenton ^e   Feng, Wenguang ^e   Jaimes, Edgar ^e   Warnock, David G ^e   Jaisser, Frederic ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CONNECTIVE TISSUE GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSPONDIN 1; THROMBOSPONDIN 2; ISOENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VENTRICLE REMODELING; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANIMAL; AORTA; BLOOD PRESSURE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENE INACTIVATION; HEART VENTRICLE; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

MUS;

ALPHA-GALACTOSIDASE; ANIMALS; AORTA; BLOOD PRESSURE; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GENE KNOCKOUT TECHNIQUES; HEART RATE; HEART VENTRICLES; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860505052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033743     Document Type: Article

References (48)

1. Desnick RJ, Ioannou YA, Eng CM, (2001) Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic Bases of Inherited Disease 8th ed. New York McGraw-Hill pp. 3733-3774.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, (1999) Prevalence of lysosomal storage disorders. J Am Med Assoc 281: 249-254.
3. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, et al. (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40.
4. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, et al. (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95: 163-168.
5. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R, (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67: 2045-2047.
6. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, et al. (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111.
7. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, et al. (2010) Prognostic indicators of renal disease progression in adults with fabry disease: natural history data from the fabry registry. Clin J Amer Soc Nephrol 5: 2220-2228.
8. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, et al. (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51: 50-59.
9. Fervenza FC, Torra R, Warnock DG, (2008) Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets and Therapy 2: 1-22.
10. Tahir H, Jackson LL, Warnock DG, (2007) Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18: 2609-2617.
11. Fervenza FC, Torra R, Lager DJ, (2008) Fabry disease: an underrecognized cause of proteinuria. Kidney intern 73: 1193-1199.
12. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, et al. (2011) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association- European Renal Association.
13. Shah JS, Elliott PM, (2005) Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr Suppl 94: 11-14; discussion 19-10.
14. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, et al. (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. European Heart J 28: 1228-1235.
15. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, et al. (2009) Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment. Circulation 119: 524-529.
16. Weidemann F, Niemann M, Warnock DG, Ertl G, Wanner C, (2011) The fabry cardiomyopathy: models for the cardiologist. Ann Rev Med 62: 59-67.
17. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, et al. (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97: 463-469.
18. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, et al. (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64: 550-555.
19. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, et al. (2005) Pediatric Fabry disease. Pediatrics 115: e344-355.
20. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ, (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68: 14-25.
21. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, et al. (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94: 2540-2544.
22. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, et al. (2003) Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298-302.
23. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, et al. (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111: 629-632.
24. Park JL, Whitesall SE, D'Alecy LG, Shu L, Shayman JA, (2008) Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35: 1156-1163.
25. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, et al. (2009) Decreased Nitric Oxide Bioavailability in a Mouse Model of Fabry Disease. J Am Soc Nephrol.
26. Rozenfeld PA, Fritz M, Blanco P, Gonzalez P, Rinaldi GJ, (2011) Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy. Canadian J Cardiol 27: 339-345.
27. Bichara M, Attmane-Elakeb A, Brown D, Essig M, Karim Z, et al. (2006) Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology 16: 36-45.
28. Sainte-Marie Y, Nguyen Dinh Cat A, Perrier R, Mangin L, Soukaseum C, et al. (2007) Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB J 21: 3133-3141.
29. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, et al. (2005) Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112: 2930-2939.
30. Whittaker P, Kloner RA, Boughner DR, Pickering JG, (1994) Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89: 397-410.
31. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, et al. (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 3025-3033.
32. Schellings MW, Pinto YM, Heymans S, (2004) Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovas Res 64: 24-31.
33. Mallon AM, Blake A, Hancock JM, (2008) EuroPhenome and EMPReSS: online mouse phenotyping resource. Nucleic Acids Res 36: D715-718.
34. Guo X, Kono Y, Mattrey R, Kassab GS, (2002) Morphometry and strain distribution of the C57BL/6 mouse aorta. Am J Physiol Heart Circ Physiol 283: H1829-1837.
35. Shu L, Murphy HS, Cooling L, Shayman JA, (2005) An in vitro model of Fabry disease. J Am Soc Nephrol 16: 2636-2645.
36. Barbey F, Qanadli SD, Juli C, Brakch N, Palacek T, et al. (2010) Aortic remodelling in Fabry disease. Eur Heart J 31: 347-353.
37. Sadick N, Thomas L, (2007) Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 16: 200-206.
38. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, et al. (2008) Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172: 1482-1490.
39. Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, et al. (2009) Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 132: 38-44.
40. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, et al. (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96: 842-846.
41. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, et al. (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS- Fabry Outcome Survey. J Med Genet 46: 548-552.
42. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P, (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11: 790-796.
43. Kouris NT, Kontogianni DD, Pavlou MT, Babalis DK, (2005) Atrioventricular conduction disturbances in a young patient with Fabry's disease without other signs of cardiac involvement. Int J Cardiol 99: 327-328.
44. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, et al. (2003) Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 41: 315-321.
45. Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z, (2005) Cardiopulmonary exercise testing in Fabry disease. Respiration 72: 504-511.
46. Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, et al. (2008) Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 38: 407-414.
47. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, et al. (2010) Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55: 758-770.
48. Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, et al. (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 5: e15033.